Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assertio Holdings, Inc. filings document formal disclosures for a Nasdaq-listed commercial pharmaceutical company, including material-event reports, annual meeting voting results, governance actions, and capital-structure matters. The record includes disclosures on common stock, convertible senior notes, tender-offer communications, and amendments to equity incentive plan provisions.
Assertio's SEC reports also cover material definitive agreements and completed asset-sale disclosures involving branded products such as INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP. These filings describe transaction documents, Regulation FD communications, shareholder approvals, executive-compensation plan matters, and operating subjects tied to the company's pharmaceutical commercialization business.
Assertio Holdings, Inc. has completed its cash merger with Zydus Lifesciences, becoming a wholly owned subsidiary and delisting its common stock from Nasdaq. Assertio stockholders are receiving $23.50 in cash per share for their holdings.
The acquisition followed a tender offer in which 4,286,488 shares, or 66.32% of outstanding shares, were validly tendered and accepted for payment. The merger closed under Delaware law without a separate shareholder vote, and all non‑appraisal shares were converted into the cash merger consideration.
The merger triggered a Fundamental Change and Make‑Whole Fundamental Change for Assertio’s 6.50% Convertible Senior Notes due 2027, of which $40 million principal was outstanding. Noteholders may either require repurchase at 100% of principal plus accrued interest on July 17, 2026, or convert during a defined period into cash based on a conversion rate tied to the $23.50 merger price.
Assertio Holdings, Inc. supplements its Solicitation/Recommendation Statement to report that the tender offer by Zara Merger Sub Inc. for all outstanding Assertio shares at $23.50 per share expired at one minute past 11:59 p.m. New York City time on June 15, 2026.
Purchaser accepted 4,286,488 Shares validly tendered and not validly withdrawn, representing 66.32% of issued and outstanding shares as of the Expiration Time. The Minimum Condition was satisfied, Purchaser will pay the Offer Price promptly, and the merger under Section 251(h) of the DGCL is expected to close on June 16, 2026, after which Assertio will be a wholly owned subsidiary and its common stock will be delisted from Nasdaq.
Zydus Lifesciences completed its tender offer for Assertio Holdings, accepting 4,286,488 Shares at $23.50 per Share.
The Offer expired at one minute after 11:59 p.m. Eastern Time on June 15, 2026, and Purchaser accepted for payment all Shares validly tendered and not validly withdrawn on June 16, 2026. The tendered Shares represented approximately 66.32% of issued and outstanding Shares as of the Expiration Time. Zydus and its offeror expect to effect a short-form merger under Section 251(h) of the DGCL promptly following acceptance, after which Assertio will be a wholly owned subsidiary, its Shares will be delisted from Nasdaq, and its Exchange Act reporting obligations will be suspended.
Assertio Holdings, Inc. is the subject of an amended Schedule 13G/A filing reporting that Nantahala Capital Management, LLC and its managers, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 0 Shares of Common Stock as of May 29, 2026.
The filing lists the reporting persons' citizenships, the issuer's principal executive office, the class (Common Stock, $0.0001 par value) and CUSIP 04546C304, and shows zero sole or shared voting and dispositive power. Signatures are dated June 2, 2026.
Assertio Holdings, Inc. recommends that stockholders tender their common shares in connection with a tender offer by Zydus Worldwide DMCC and its wholly owned Merger Sub to purchase all outstanding shares at $23.50 per share in cash, pursuant to an Agreement and Plan of Merger.
The Schedule 14D-9 states that as of May 14, 2026, 6,462,180 Shares were issued and outstanding and that the Merger will follow the Offer under Section 251(h) of the Delaware General Corporation Law.
Assertio Holdings, Inc.: a subsidiary of Zydus Lifesciences (Zara Merger Sub Inc.) has launched a cash tender offer to acquire all outstanding shares of Assertio for $23.50 per share, payable in cash, pursuant to the Offer to Purchase dated May 18, 2026. The transaction is structured as a tender offer with an Agreement and Plan of Merger dated May 13, 2026. The Offer is not subject to a financing condition; other terms, conditions and supporting tender agreements are described in the Offer to Purchase and related exhibits.
Assertio Holdings, Inc. entered into an Agreement and Plan of Merger on May 13, 2026 under which Zydus Worldwide DMCC, through its wholly owned Purchaser, will commence a cash tender offer on May 18, 2026 to acquire all outstanding common shares for $23.50 per share. If completed, Purchaser will merge into Assertio and Assertio will become a wholly owned subsidiary of Parent.
The company agreed to pursue a contemporaneous offer and consent solicitation for its 6.50% Convertible Senior Notes due 2027, but Parent waived the requirement that Assertio commence that Note Offer. The Merger will constitute a "Fundamental Change" and a "Make-Whole Fundamental Change" under the Indenture, giving holders rights including repurchase at 100% of principal plus accrued interest and an increased conversion rate during the Make-Whole period.
Assertio Holdings, Inc. announced that it has entered into a Merger Agreement under which Zydus Worldwide DMCC, through a wholly owned subsidiary, will launch a cash tender offer to acquire all outstanding Assertio common shares for $23.50 per share. After the tender offer is completed, the buyer’s subsidiary will merge into Assertio, which will then become a wholly owned subsidiary of Zydus.
The Merger will trigger a “Fundamental Change” and a “Make-Whole Fundamental Change” under Assertio’s 6.50% Convertible Senior Notes due 2027. Noteholders will have the right to require repurchase of their notes for cash at 100% of principal plus accrued and unpaid interest, or to convert into the merger consideration at an increased conversion rate during the specified make‑whole period.
Assertio Holdings, Inc. director Heather L. Mason reported making bona fide gifts of a total of 13,332 shares of Common Stock on May 13, 2026. One gift of 6,666 shares reduced an indirect position held by a trust to 6,666 shares, and another 6,666-share gift left 20,944 shares held directly.
Assertio Holdings, Inc. received a preliminary communication that Zara Merger Sub Inc., a subsidiary of Zydus Lifesciences Ltd., intends to commence a tender offer to purchase all issued and outstanding common shares at $23.50 per share, less any applicable withholding taxes. The communication is a preliminary disclosure and the tender offer has not commenced; formal tender offer materials (Schedule TO) and the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 will be filed with the SEC.
The offeror identifies Parent entities as controllers of the purchaser but states they are not otherwise participating. The communication includes a press release dated May 13, 2026 and cautions that closing is subject to customary conditions and regulatory approvals.